Patents by Inventor RANA RAIS

RANA RAIS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11932664
    Abstract: Methods and compounds are disclosed for treating a disease or condition by inhibiting PSMA (Prostate Specific Membrane Antigen) using prodrugs of 2-PMPA.
    Type: Grant
    Filed: May 9, 2022
    Date of Patent: March 19, 2024
    Assignees: THE JOHNS HOPKINS UNIVERSTY, INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I.
    Inventors: Barbara Slusher, Rana Rais, Marcela Krecmerova, Tomas Tichy, Pavel Majer, Andrej Jancarik
  • Patent number: 11926640
    Abstract: The disclosure provides compounds having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON). The disclosure also provides compounds having formula (I) for use in treating cancer.
    Type: Grant
    Filed: March 19, 2021
    Date of Patent: March 12, 2024
    Assignees: The Johns Hopkins University, Ústav organické chemie a biochemie AV {hacek over (C)}R, v.v.i.
    Inventors: Barbara Slusher, Rana Rais, Lukas Tenora, Pavel Majer, Andrej Jancarik
  • Publication number: 20240024347
    Abstract: Prodrugs of 6-mercaptopurine (6-MP) and methods of their use for treating cancers and autoimmune diseases are disclosed.
    Type: Application
    Filed: August 25, 2021
    Publication date: January 25, 2024
    Inventors: Barbara Slusher, Kathryn Lemberg, Rana Rais, Pavel Majer, Marcela Krecmerova
  • Patent number: 11866394
    Abstract: Prodrugs of hydroxamate-based GCPII inhibitors and methods of their use for treating a disease or condition are disclosed.
    Type: Grant
    Filed: July 12, 2021
    Date of Patent: January 9, 2024
    Assignees: THE JOHNS HOPKINS UNIVERSTY, INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I.
    Inventors: Barbara Slusher, Rana Rais, Jan Vavra, Tomas Tichy, Pavel Majer, Andrej Jancarik, Lukas Tenora
  • Publication number: 20230416294
    Abstract: Novel N4-substituted decitabine analogs are disclosed that exhibit promising in vitro and in vivo therapeutic activity. These novel compounds were shown to be resistant to deamination via cytidine deaminase (CDA) metabolism and provide a unique pharmacokinetic profile versus decitabine, while retaining the ability to induce DNA demethylation in target cells. These novel compounds can be used for treating hematological cancers, as well for new therapeutic interventions, including bacterial or viral pneumonia, acute respiratory distress syndrome, pulmonary fibrosis, transplantation and checkpoint inhibitor-induced adverse events, including pneumonitis.
    Type: Application
    Filed: August 10, 2021
    Publication date: December 28, 2023
    Inventors: Barbara Slusher, Rana Rais, Franco D'Alessio, Pavel Majer, Marcela Krecmerova, Srinivasan Yegnasubramanian
  • Publication number: 20230372499
    Abstract: Dendrimer compositions and methods for the treatment of cancer or autoimmune diseases are described. The compositions include dendrimers complexed or conjugated with one or more active agents for the treatment or alleviation of one or more symptoms of cancer or autoimmune diseases. The dendrimers may include one or more ethylene diamine-core poly(amidoamine) (PAMAM) hydroxyl-terminated generation-4, 5, 6, 7, 8, 9, or 10 dendrimers. The active agents may be immunomodulatory agents such as STING agonists, CSF1R inhibitors, PARP inhibitors, VEGFR tyrosine kinase inhibitors, MEK inhibitors, glutaminase inhibitors, TIE II antagonists, and CXCR2 inhibitors, and STING antagonists. Methods of using the dendrimer compositions to treat cancer, bone disease or inflammatory diseases are also provided.
    Type: Application
    Filed: October 7, 2022
    Publication date: November 23, 2023
    Inventors: Jeffrey Cleland, Rishi Sharma, Minghao Sun, Santiago Appiani, Barbara Slusher, Rana Rais, Kannan Rangaramanujam
  • Patent number: 11712435
    Abstract: Prodrugs of mebendazole and methods for their use in treating a disease, disorder, or disorder, including cancer, are disclosed.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: August 1, 2023
    Assignees: THE JOHNS HOPKINS UNIVERSITY, INSTITUTE OF ORGANIC CHEMISTRY & BIOCHEMISTRY AS CR V.V.I.
    Inventors: Barbara Slusher, Rana Rais, Gregory Riggins, Pavel Majer, Tomas Tichy, Jan Vavra, Andrej Jancarik, Lukas Tenora
  • Publication number: 20230218581
    Abstract: Compositions of dendrimers conjugated with one or more therapeutic agents that decrease exosome secretion and methods of use thereof for treating, alleviating, and/or preventing one or more symptoms associated with one or more neurological disease or disorders, cancer, inflammatory diseases, bacterial and viral infections, and other disorders have been developed. Preferably, the therapeutic agents are one or more agents that inhibit or reduce activity and/or quantity of neutral sphingomyelinase 2 (nSMase2) such as small molecule inhibitors of nSMase2. Compositions are particularly suited for reducing A? plaque formation, reducing tau propagation, improving cognition, or combinations thereof in a subject with psychiatric and neurological disorders. Compositions are also suited for treating, alleviating, and/or preventing one or more symptoms associated with cancer, bacterial and viral infections, and inflammatory diseases.
    Type: Application
    Filed: April 23, 2021
    Publication date: July 13, 2023
    Inventors: Sujatha Kannan, Rana Rais, Kannan Rangaramanujam, Anjali Sharma, Barbara Slusher, Carolyn Tallon, Ajit Thomas, Ranjeev Kumar Pandey, Jonathan Powell
  • Publication number: 20230128984
    Abstract: GCPII inhibitors comprising 2-(phosphonomethyl) pentanedioic acid (2-PMPA) conjugated to a bile acid and their use for treating a disease or condition associated with elevated levels of GCPII, including inflammatory bowel disease.
    Type: Application
    Filed: January 29, 2021
    Publication date: April 27, 2023
    Inventors: Barbara Slusher, Diane E. Peters, Rana Rais, Pavel Majer, Lukas Tenora, Ivan Snajdr
  • Publication number: 20230115651
    Abstract: Methods and compounds are disclosed for treating a disease or condition by inhibiting PSMA (Prostate Specific Membrane Antigen) using prodrugs of 2-PMPA
    Type: Application
    Filed: May 9, 2022
    Publication date: April 13, 2023
    Inventors: BARBARA SLUSHER, RANA RAIS, MARCELA KRECMEROVA, TOMAS TICHY, PAVEL MAJER, ANDREJ JANCARIK
  • Publication number: 20230075584
    Abstract: The presently disclosed subject matter provides methods for treating and diagnosing neurological diseases or disorders using intranasal administration of glutamate carboxypeptidase II (GCP-II) inhibitors in a subject. Methods for imaging GCP-II in a subject, including imaging of the brain and/or peripheral nervous system, also are provided.
    Type: Application
    Filed: May 5, 2022
    Publication date: March 9, 2023
    Inventors: BARBARA S. SLUSHER, RANA RAIS
  • Publication number: 20230028516
    Abstract: Prodrugs of itaconic acid and 1- and 4-methyl itaconic acid and their use for treating a disease, disorder, or condition associated with inflammation are disclosed.
    Type: Application
    Filed: October 29, 2020
    Publication date: January 26, 2023
    Inventors: Barbara Slusher, Mohameed Islam, Rana Rais, Luis Garza, Benjamin Bell, Pavel Majer, Lukas Tenora, Ivan Snajdr, Marcela Krecmerova
  • Publication number: 20230025922
    Abstract: Methods for the use of prodrugs of itaconic acid and 1- and 4-methyl itaconic acid for inducing hair growth and treating an inflammatory, or immune activation (adaptive or innate), skin condition or other condition associated with hair loss are disclosed.
    Type: Application
    Filed: October 29, 2020
    Publication date: January 26, 2023
    Inventors: Luis Garza, Mohameed Islam, Barbara Slusher, Rana Rais
  • Publication number: 20230009398
    Abstract: Glutamine antagonists and their use for treating oncological, immunological, and neurological diseases are disclosed. Also disclosed are methods for treating an oncological, immunological, infectious or neurological disease or disorder, the method comprising administering to a subject in need of treatment thereof a therapeutically effective amount of a glutamine antagonist of the disclosure or the pharmaceutical composition thereof. Also disclosed are methods of enhancing the effects of an immune checkpoint inhibitor, enabling a subject to respond to an immune checkpoint inhibitor, or enabling the toxicity or the dose or number of treatments with an immune checkpoint inhibitor to be reduced, comprising administering to a subject in need of treatment thereof a therapeutically effective amount of a glutamine antagonist of the disclosure or the pharmaceutical composition thereof, and an immune checkpoint inhibitor.
    Type: Application
    Filed: October 5, 2018
    Publication date: January 12, 2023
    Inventors: Barbara SLUSHER, Rana RAIS, Pavel MAJER, Lukas TENORA, Katerina NOVOTNA, Jesse ALT
  • Patent number: 11331271
    Abstract: Methods for buccally, sublingually, or intranasally administering a prodrug of propofol to a subject in need of treatment thereof in an amount sufficient to deliver a therapeutically effective amount of propofol to the subject are disclosed.
    Type: Grant
    Filed: May 25, 2017
    Date of Patent: May 17, 2022
    Assignee: The Johns Hopkins University
    Inventors: Barbara Slusher, Rana Rais, James Vornov
  • Patent number: 11325931
    Abstract: Methods and compounds are disclosed for treating a disease or condition by inhibiting PSMA (Prostate Specific Membrane Antigen) using prodrugs of 2-PMPA.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: May 10, 2022
    Assignees: The Johns Hopkins University, Inst of Organic Chem. and Biochemistry AS CR V.V.I
    Inventors: Barbara Slusher, Rana Rais, Marcela Krecmerova, Tomas Tichy, Pavel Majer, Andrej Jancarik
  • Publication number: 20210355079
    Abstract: Prodrugs of hydroxamate-based GCPII inhibitors and methods of their use for treating a disease or condition are disclosed.
    Type: Application
    Filed: July 12, 2021
    Publication date: November 18, 2021
    Inventors: Barbara Slusher, Rana Rais, Jan Vavra, Tomas Tichy, Pavel Majer, Andrej Jancarik, Lukas Tenora
  • Patent number: 11059775
    Abstract: Prodrugs of hydroxamate-based GCPII inhibitors and methods of their use for treating a disease or condition are disclosed.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: July 13, 2021
    Assignees: The Johns Hopkins University, INSTITUTE OF ORGANIC CHEMISTRY & BIOCHEMISTRY
    Inventors: Barbara Slusher, Rana Rais, Jan Vavra, Tomas Tichy, Pavel Majer, Andrej Jancarik, Lukas Tenora
  • Publication number: 20210205271
    Abstract: Prodrugs of mebendazole and methods for their use in treating a disease, disorder, or disorder, including cancer, are disclosed.
    Type: Application
    Filed: February 8, 2019
    Publication date: July 8, 2021
    Inventors: Barbara Slusher, Rana Rais, Gregory Riggins, Pavel Majer, Tomas Tichy, Jan Vavra, Andrej Jancarik
  • Publication number: 20210206787
    Abstract: The disclosure provides compounds having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set firth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON). The disclosure also provides compounds having formula (I) for use in treating cancer.
    Type: Application
    Filed: March 19, 2021
    Publication date: July 8, 2021
    Inventors: Barbara SLUSHER, Rana RAIS, Lukas TENORA, Pavel MAJER, Andrej JANCARIK